カテゴリー： 世界, Grand View Research

世界のRSウイルス（RSV）診断市場（2025年～2030年）

【英語タイトル】Respiratory Syncytial Virus Diagnostics Market Size, Share & Trends Analysis Report By Product (DFA, RADT, Molecular Diagnostics, Chromatographic Immunoassay), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Grand View Researchが出版した調査資料（GVR68038-680-6）・商品コード：GVR68038-680-6
・発行会社（調査会社）：Grand View Research
・発行日：2024年12月
・ページ数：150
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥892,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,042,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,342,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

世界のRSウイルス（RSV）診断市場は、2024年に約62.7億米ドルと推計され、2025～2030年に年平均5.81％で成長すると予測されている。乳幼児や高齢者を中心とした呼吸器感染症の増加、新生児人口の拡大、院内および在宅での体外診断・POC（ポイントオブケア）検査への需要の高まりが主な成長要因である。RSVは5歳未満児で年間約3,300万件の下気道感染を引き起こし、そのうち300万件超が入院に至るとされる。米国だけでも、5歳未満児で年間5.8万～8万件の入院と100～300件の死亡、65歳以上の高齢者で6万～16万件の入院と6,000～1万件の死亡が発生しており、秋冬の流行シーズンには医療提供体制への負荷が大きい。このため迅速かつ正確な診断ソリューションへのニーズが高まっている。

技術面では、RT-PCRなどの分子診断が低ウイルス量でも高精度に検出できることから重要性を増しており、AIや自動化を組み合わせたシステムも登場している。こうした高度診断技術は臨床・研究の双方で不可欠なツールとなりつつあり、診断の信頼性向上とワークフロー効率化を通じて市場拡大に寄与している。一方で、先進的な分子検査やPOC機器はコストが高く、低・中所得国では導入障壁となっているうえ、地域によって検査プロトコルや償還制度が標準化されていない点、RSV検査そのものへの認知不足、流行が季節要因に左右され需要が変動しやすい点などが成長抑制要因となっている。

市場特性としては、技術革新の度合いは高く、RT-PCR、迅速抗原検査、POC機器、AI搭載システムなど高感度・高特異度かつ短時間で結果が得られる製品開発が活発である。M&Aは中程度で、大手企業によるポートフォリオ補完型の買収が一部みられるが、研究開発や提携を通じた有機的成長が中心である。診断薬はFDAやEMAなどの規制当局による厳格な承認プロセスの影響を強く受ける一方、臨床評価の高度化や安全性確保を通じてイノベーションを促す側面もある。代替手段としては臨床所見やX線などが存在するものの、分子・抗原検査ほどの感度・特異度はなく、実質的な代替脅威は低い。エンドユーザーは病院と臨床検査ラボが中心だが、クリニックや家庭向けのPOC・OTC検査の普及により裾野が広がっている。

製品別では、クロマトグラフィー免疫測定法（ラテラルフロー等）が2024年に市場シェア27.38％で最大セグメントとなり、迅速性・簡便性・コスト効率の高さから今後も高成長が見込まれる。AbbottのBinaxNOW RSVやQuidelのSofia RSV FIAなどが代表例であり、15～30分程度で結果が得られることから、特に小児・高齢者の急性呼吸器感染症の現場診断に広く用いられている。また、ゲルマイクロドロップレット技術は高感度・高スループットかつ多項目同時検出（マルチプレックス）を可能にする新技術として注目されており、今後最も高い成長率が期待される。

エンドユース別では、重症例への対応拠点である病院が2024年に41.09％を占め最大であり、今後も高精度の分子検査や免疫測定、POC機器への投資を背景に優位性を維持する見込みである。一方、OTCの迅速検査キットや在宅検査へのニーズ拡大によりホームケア分野も大きく伸長するとみられる。

地域別では、北米が2024年に41.18％で最大市場となっており、先進的な医療インフラ、高い診断技術導入率、政府・民間の投資拡大、RSVに対する認知向上が成長を支えている。欧州も重要市場で、英国、フランス、ドイツなどで早期診断・治療体制の強化に伴い迅速・低コスト検査の採用が進んでいる。アジア太平洋は中国・インド・日本などの人口増加と医療投資、安価で迅速な診断ソリューションの普及を背景に、最も高い成長率が見込まれる新興市場である。中南米、中東・アフリカも医療インフラ整備とRSV認知向上により有望地域とされ、ブラジル、サウジアラビアなどで需要の拡大が続いている。

競合環境としては、Abbott、Thermo Fisher Scientific、QuidelOrtho、BD、Roche、Bio-Rad、bioMérieux、DiaSorin、Cepheid、Merck、Siemens Healthcare、Quest Diagnosticsなどグローバル大手が分子診断から迅速抗原・POC検査まで幅広い製品ラインアップを展開し、市場をリードしている。これらに加え、LumiraDxやCoris BioConceptなど新興企業もAI、自動化、マイクロフルイディクス技術を活用した次世代RSV診断ソリューションで差別化を図っており、今後も高感度・迅速・利便性を追求した製品開発競争が継続すると見込まれる。

The global respiratory syncytial virus diagnostics market size was estimated at USD 6.27 billion in 2024 and is projected to grow at a CAGR of 5.81% from 2025 to 2030. The growth of the market is attributed to the increasing incidence of respiratory infections, rising neonatal population base, and high demand for in-vitro diagnostics & point of care facilities. Advances in diagnostic technologies, including molecular assays and point-of-care (POC) testing, have enhanced the speed and precision of RSV detection, creating lucrative opportunities for market players. Moreover, government initiatives and funding to combat infectious diseases are further fueling the market’s growth.

Respiratory syncytial virus (RSV) is a highly prevalent viral infection, particularly impacting infants, young children, and older adults. Globally, RSV is estimated to cause approximately 33 million acute lower respiratory tract infections annually in children under five years, with over 3 million cases requiring hospitalization. In the U.S., RSV leads to 58,000-80,000 hospitalizations and 100-300 deaths among children under five each year, as well as 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults aged 65 and older. Seasonal outbreaks typically occur during fall and winter, significantly impacting healthcare systems, and highlighting the critical need for effective diagnostic and preventive measures.

Technological advancements are another critical driver of market growth, as manufacturers focus on developing more sensitive and specific diagnostic tests. Molecular diagnostic methods, such as reverse transcription polymerase chain reaction (RT-PCR), have gained importance for their high accuracy and ability to detect low viral loads. These innovations have boosted RSV diagnostic’s reliability, making them indispensable tools in clinical and research settings. The integration of artificial intelligence (AI) and automation in diagnostics is also expected to streamline workflows and enhance the efficiency of RSV detection.

Growing awareness about the severity and impact of respiratory syncytial virus (RSV) infections, coupled with increasing healthcare spending, is a major driver of market growth. Public health campaigns, educational initiatives, and media coverage have highlighted the risks associated with RSV, particularly for vulnerable populations such as infants and the elderly, prompting a surge in demand for timely diagnostic solutions. Rising healthcare expenditure, especially in developed and emerging economies, has enabled the adoption of advanced diagnostic technologies and infrastructure improvements. Governments and private organizations are investing in research, screening programs, and preventive strategies, further accelerating the integration of RSV diagnostics into routine healthcare practices. This heightened focus on early diagnosis and treatment aligns with the broader shift towards patient-centric and value-based care, boosting the market’s growth.

However, the high cost associated with advanced diagnostic technologies, such as molecular assays and point-of-care devices, which can limit their accessibility, particularly in low- and middle-income regions, is one of the major factors restraining the growth of the market. In addition, the lack of standardized testing protocols and inconsistent reimbursement policies in some regions pose challenges to market adoption. Awareness about RSV diagnostics remains low in certain populations, further restricting demand. Moreover, the seasonal nature of RSV outbreaks creates fluctuating demand, making it difficult for manufacturers and healthcare providers to maintain consistent supply chains and resources throughout the year.

The degree of innovation in the market is high, as companies continuously develop and introduce more advanced, sensitive, and rapid diagnostic technologies. For example, the use of molecular diagnostics like RT-PCR has significantly improved detection accuracy, while rapid antigen tests and point-of-care (POC) devices enable faster results for timely patient management. Furthermore, the integration of AI and automation into diagnostic workflows has further enhanced the efficiency and accuracy of RSV testing, indicating a strong push for innovation in this space.

The level of mergers and acquisitions (M&A) activities in market is medium. While there have been some strategic acquisitions by major diagnostic companies to strengthen their product portfolios and expand market reach, such as Abbott’s acquisition of Alere, the market is not experiencing a high volume of M&A activity. Companies are primarily focusing on organic growth through research and development or partnerships to innovate and capture market share.

[Market Segmentation]

Respiratory Syncytial Virus Diagnostics Product Outlook (Revenue, USD Billion, 2018 – 2030)

Direct Fluorescent Antibody (DFA) Method
Rapid Antigen Diagnostic Test (RADT)
Molecular Diagnostics
Chromatographic Immunoassay
Gravity Driven Test
Oligo chromatography (OC)
Diagnostic Imaging
Gel Microdroplets
Flow Cytometry
Others

Respiratory Syncytial Virus Diagnostics End use Outlook (Revenue, USD Billion, 2018 – 2030)

Hospitals
Laboratory
Clinics
Homecare

❖ レポートの目次 ❖

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and End use outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Respiratory Syncytial Virus Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of Respiratory Syncytial Virus (RSV) Infections
3.2.1.2. Advancements in diagnostics technologies
3.2.1.3. Growing awareness and healthcare spending
3.2.2. Market restraint analysis
3.2.2.1. High cost associated with advanced diagnostic tests
3.2.2.2. Lack of awareness in developing reagions
3.3. Respiratory Syncytial Virus Diagnostics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Technological landscape
3.3.2.4. Social landscape
3.3.2.5. Environmental landscape
Chapter 4. Respiratory Syncytial Virus Diagnostics Market: Product Estimates & Trend Analysis
4.1. Global Respiratory Syncytial Virus Diagnostics Market: Product Dashboard
4.2. Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
4.3. Global Respiratory Syncytial Virus Diagnostics Market by Product , Revenue
4.4. Direct Fluorescent Antibody (DFA) Method
4.5. Rapid Antigen Diagnostic Test (RADTs)
4.5.1. Rapid Antigen Diagnostic Test (RADTs) market estimates and forecasts 2018 to 2030 (USD Billion)
4.6. Molecular Diagnostics
4.6.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Billion)
4.7. Chromatographic Immunoassay
4.7.1. Chromatography immunoassay market estimates and forecasts 2018 to 2030 (USD Billion)
4.7.2. Gravity Driven Test
4.7.2.1. Gravity driven test market estimates and forecasts 2018 to 2030 (USD Billion)
4.7.3. Oligochromatography (OC)
4.7.3.1. Oligochromatography (OC) market estimates and forecasts 2018 to 2030 (USD Billion)
4.8. Diagnostic Imaging
4.8.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Billion)
4.9. Gel Microdroplets
4.9.1. Gel microdroplets market estimates and forecasts 2018 to 2030 (USD Billion)
4.10. Flow Cytometry
4.10.1. Flow cytometry market estimates and forecasts 2018 to 2030 (USD Billion)
4.11. Others
4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. Respiratory Syncytial Virus Diagnostics Market: End use Estimates & Trend Analysis
5.1. Global Respiratory Syncytial Virus Diagnostics Market: End use Dashboard
5.2. Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
5.3. Global Respiratory Syncytial Virus Diagnostics Market by End use, Revenue
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
5.5. Laboratory
5.5.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Billion)
5.6. Clinics
5.6.1. Clinics market estimates and forecasts 2018 to 2030 (USD Billion)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 6. Respiratory Syncytial Virus Diagnostics Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. BD (Becton, Dickinson, and Company)
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Novartis AG
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Abbott
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. QuidelOrtho Corporation
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Thermo Fisher Scientific Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Bio-Rad Laboratories, Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. F. Hoffmann-La Roche Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. BIOMÉRIEUX
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. DiaSorin S.p.A.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Merck KGaA
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Coris BioConcept
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Siemens Healthineers AG
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Quest Diagnostics Incorporated
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Product benchmarking
7.3.16.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 4 Global Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 5 Global Oncology Companion Diagnostic, by Region, 2018 – 2030 (USD Billion)
Table 6 North America Oncology Companion Diagnostic, by Country, 2018 – 2030 (USD Billion)
Table 7 North America Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 8 North America Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 9 U.S. Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 10 U.S. Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 11 Canada Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 12 Canada Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 13 Mexico Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 14 Mexico Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 15 Europe Oncology Companion Diagnostic, by Country, 2018 – 2030 (USD Billion)
Table 16 Europe Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 17 Europe Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 18 Germany Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 19 Germany Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 20 UK Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 21 UK Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 22 France Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 23 France Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 24 Italy Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 25 Italy Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 26 Spain Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 27 Spain Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 28 Denmark Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 29 Denmark Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 30 Sweden Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 31 Sweden Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 32 Norway Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 33 Norway Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 34 Asia Pacific Oncology Companion Diagnostic, by Country, 2018 – 2030 (USD Billion)
Table 35 Asia Pacific Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 36 Asia Pacific Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 37 China Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 38 China Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 39 Japan Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 40 Japan Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 41 India Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 42 India Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 43 South Korea Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 44 South Korea Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 45 Australia Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 46 Australia Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 47 Thailand Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 48 Thailand Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 49 Latin America Oncology Companion Diagnostic, by Country, 2018 – 2030 (USD Billion)
Table 50 Latin America Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 51 Latin America Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 52 Brazil Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 53 Brazil Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 54 Argentina Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 55 Argentina Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 56 Middle East & Africa Oncology Companion Diagnostic, by Country, 2018 – 2030 (USD Billion)
Table 57 Middle East & Africa Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 58 Middle East & Africa Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 59 South Africa Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 60 South Africa Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 61 Saudi Arabia Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 62 Saudi Arabia Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 63 UAE Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 64 UAE Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)
Table 65 Kuwait Oncology Companion Diagnostic, by Product, 2018 – 2030 (USD Billion)
Table 66 Kuwait Oncology Companion Diagnostic, by End use, 2018 – 2030 (USD Billion)



★調査レポート[世界のRSウイルス（RSV）診断市場（2025年～2030年）] (コード：GVR68038-680-6)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のRSウイルス（RSV）診断市場（2025年～2030年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 脳磁図検査の世界市場2025-2030
  • 空カプセルの世界市場（～2030年）
  • リキッドバイオプシーの世界市場（～2030年）
  • バスバーの世界市場（～2030年）
  • フラットガラスの世界市場（～2030年）
  • 自動車用ヒューズの世界市場（～2030年）
  • ビデオ管理システム（VMS）の世界市場（～2030年）
  • 世界の温度制御半導体チラー市場（～2030年）
  • 脳磁図の世界市場2023年-2030年
  • 細胞培養培地の世界市場2025-2030

    • ◆H&Iグローバルリサーチのお客様（例）◆